Cerus Corporation is a medical devices business based in the US. Cerus Corporation shares (CERS) are listed on the NASDAQ and all prices are listed in US Dollars. Cerus Corporation employs 625 staff and has a trailing 12-month revenue of around $170 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.08 |
|---|---|
| 52-week range | $1.21 - $2.59 |
| 50-day moving average | $2.12 |
| 200-day moving average | $1.96 |
| Wall St. target price | $4.38 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.13 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.08 from 2024-09-05
| 1 week (2024-08-30) | -7.96% |
|---|---|
| 1 month (2024-08-06) | -5.02% |
| 3 months (2024-06-06) | 10.05% |
| 6 months (2024-03-06) | -14.05% |
| 1 year (2023-09-06) | 20.93% |
|---|---|
| 2 years (2022-09-06) | -47.07% |
| 3 years (2021-09-03) | 6.49 |
| 5 years (2019-09-06) | 5.05 |
| Revenue TTM | $170 million |
|---|---|
| Gross profit TTM | $87.1 million |
| Return on assets TTM | -4.71% |
| Return on equity TTM | -47.34% |
| Profit margin | -14.15% |
| Book value | $0.27 |
| Market Capitalization | $418.8 million |
TTM: trailing 12 months
We're not expecting Cerus Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Cerus Corporation's shares have ranged in value from as little as $1.205 up to $2.585. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerus Corporation's is 1.201. This would suggest that Cerus Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California. .
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.